ライフサイエンスコーパス: diagnostic assay

1 TP) as an illustrative example of a low cost diagnostic assay.

2 r PCR enzyme immunoassay (PCR-EIA) used as a diagnostic assay.

3 ng that this system could be the basis for a diagnostic assay.

4 r PCR based on IS2404 has shown promise as a diagnostic assay.

5 e and used to develop a species-specific PCR diagnostic assay.

6 ively small and generally only used a single diagnostic assay.

7 f a specific polymerase chain reaction-based diagnostic assay.

8 .J.) is a sensitive and specific noninvasive diagnostic assay.

9 mass spectrometry (MALDI-TOF MS) and a fucK diagnostic assay.

10 rain collections to enable assessment of new diagnostic assays.

11 ng assays) as well as for portable low-power diagnostic assays.

12 s (sibling 3-5) were tested using a range of diagnostic assays.

13 combinant affinity proteins for use in rapid diagnostic assays.

14 tention as a potential platform for low-cost diagnostic assays.

15 this gene has served as the best target for diagnostic assays.

16 ghput screens for pharmacological agents and diagnostic assays.

17 d costs are significant limiting factors for diagnostic assays.

18 is important when interpreting C. difficile diagnostic assays.

19 ificant improvement over currently available diagnostic assays.

20 f microarray hybridization data and clinical diagnostic assays.

21 ive alternative to blood for many biomedical diagnostic assays.

22 t in identifying both therapeutics and rapid diagnostic assays.

23 e fingerprints for microarray-based pathogen diagnostic assays.

24 peutic applications, as well as steady state diagnostic assays.

25 ted as potential probes for microarray-based diagnostic assays.

26 g an amenable method for automatic RAM-based diagnostic assays.

27 ints for design of microarray-based pathogen diagnostic assays.

28 st in using this technology as the basis for diagnostic assays.

29 the usefulness of comparative evaluations of diagnostic assays.

30 sily produced alternative antigen for use in diagnostic assays.

31 potential wide use in clinical research and diagnostic assays.

32 ild transmission, and the development of new diagnostic assays.

33 de application to a large number of clinical diagnostic assays.

34 as potential candidates for vaccines and/or diagnostic assays.

35 allow the development of novel therapies and diagnostic assays.

36 by Sanger sequencing or commercial molecular diagnostic assays.

37 extremely low concentrations of analytes in diagnostic assays.

38 idates and for developing improved serologic diagnostic assays.

39 manufacture of calibrators and controls for diagnostic assays.

40 munologically based therapies and prognostic/diagnostic assays.

41 n be used to develop new dengue vaccines and diagnostic assays.

42 e, and also will lead to a new generation of diagnostic assays.

43 erefore serve as a positive control in Ebola diagnostic assays.

44 system for either genetic analysis or other diagnostic assays.

45 r analytical devices and other point-of-care diagnostic assays.

46 t of technology for the rapid development of diagnostic assays.

47 orated with microfluidic or laboratory scale diagnostic assays.

48 ations in rapid, minimally invasive clinical diagnostic assays.

49 llow-up studies will yield highly innovative diagnostic assays.

50 apid and reliable confirmation of disease by diagnostic assays.

51 or the development of novel therapeutics and diagnostic assays.

52 indly tested with the gold standard and smpB diagnostic assays.

53 ogical surface functionalization for bedside diagnostic assays.

54 e samples that were RV positive in multiplex diagnostic assays.

55 cs and biomarker discovery, and for clinical diagnostic assays.

56 ints but are not widely used as reporters in diagnostic assays.

57 Using the novel smpB diagnostic assay, 100% concordance was observed with the

58 nificant increase in the number of molecular diagnostic assays, achievement of amplification directly

59 s of detection of rotavirus were compared by diagnostic assay and specimen type.

60 s disease makes the development of sensitive diagnostic assays and antemortem sampling techniques cru

61 s disease makes the development of sensitive diagnostic assays and antemortem sampling techniques cru

62 able the development of genetic barcodes for diagnostic assays and clinical studies.

63 sential for designing broadly cross-reactive diagnostic assays and dissecting the immune response to

64 d for the development of clinically relevant diagnostic assays and evaluation of therapeutic agents a

65 misdiagnosed because of low availability of diagnostic assays and expertise and classified as bullou

66 or investigating pathogenesis and developing diagnostic assays and for vaccine development.

67 d source of organisms for the development of diagnostic assays and forming a basis for future studies

68 duction of cultivation-independent molecular diagnostic assays and highly multiplexed serologic analy

69 bility of new improved strategies to support diagnostic assays and methods for drug treatment monitor

70 channel is important for the development of diagnostic assays and microreactors and for performing f

71 generated structures as bioactive probes for diagnostic assays and molecular transport junctions.

72 ied new cancer pathways and led to molecular diagnostic assays and molecular-targeted chemotherapies

73 ded for use in clinical research to evaluate diagnostic assays and not for individual patient diagnos

74 rotein levels were quantified using standard diagnostic assays and nuclear magnetic resonance (NMR) s

75 uidelines have been published to standardise diagnostic assays and once implemented may yield more ac

76 c shear would lead to the development of new diagnostic assays and pave the way to clinical approache

77 HCV), and hepatitis B virus (HBV) can affect diagnostic assays and therapeutic interventions.

78 Consequently, diagnostic assays and therapy for ITP lack specificity.

79 pB, and development of methylated OmpB-based diagnostic assays and vaccine candidates.

80 recombination and for the design of various diagnostic assays and vaccine constructs.

81 can help in selecting optimal candidates for diagnostic assays and vaccine development.

82 d be considered in the future development of diagnostic assays and vaccine preparations.

83 tivity and specificity expected of PCR-based diagnostic assays and will contribute new insight regard

84 pid prototyping of hand-held, visually read, diagnostic assays (and other microfluidic systems) based

85 rovides insight into the pathogenic process, diagnostic assays, and potential therapeutic agents.

86 e, the potential benefits and limitations of diagnostic assays, and the likelihood that agents in dev

87 MP Diagnostics assay, in 29.5% by the Axiom Diagnostics assay, and in 18% by the Mikrogen assay.

88 solations in research laboratories, clinical diagnostics assays, and cell therapy manufacturing.

89 riations of MSPs and in their utilities in a diagnostic assay are discussed.

90 Mainstream diagnostic assays are challenged by their intrinsic dive

91 rgence of new viral variants and ensure that diagnostic assays are contemporary and fully optimized.

92 ultiplexed, sensitive, and on-chip molecular diagnostic assays are essential in both clinical and res

93 Paper-based diagnostic assays are gaining increasing popularity for

94 Recently developed filarial molecular diagnostic assays are highly sensitive and specific but

95 operation and safety, as well as Ebola virus diagnostic assays, are described and discussed; in addit

96 volves development of fluorescent cell-based diagnostic assay as a new approach in high-throughput sc

97 ave heightened the need available commercial diagnostic assays as well as standardized methods for de

98 t of a novel, inexpensive, and user-friendly diagnostic assay based on a reverse transcription-insula

99 For this study a diagnostic assay based on CPT was developed for the dete

100 e a serious obstacle in the development of a diagnostic assay based on TaqMan PCR; however, the quant

101 A homogeneous DNA diagnostic assay based on template-directed primer exten

102 The feasibility of developing molecular diagnostic assays based on the accelerated photobleachin

103 Epidemiological and clinical diagnostic assays benefit from accurate detection of del

104 the development of the BTA stat and BTA TRAK diagnostic assays, both of which make use of two factor

105 w WGS can be exploited to evaluate molecular diagnostic assays by using publicly available data, onli

106 , and reaction chambers such that the entire diagnostic assay can be automatically executed on a sing

107 This single-tube diagnostic assay can be performed in 2 h or less and can

108 -consuming; recent advances, translated into diagnostic assays, can improve testing and facilitate ty

109 Current commercial diagnostic assays cannot differentiate EV-D68 from other

110 or a highly sensitive and specific molecular diagnostic assay capable of detecting the natural geneti

111 A sensitive, low-cost diagnostic assay capable of rapidly evaluating the effec

112 However, current diagnostic assays commonly require long assay time, soph

113 Molecular diagnostic assays detected Borrelia miyamotoi in the per

114 lications for both C. pneumoniae vaccine and diagnostic assay development.

115 With impressive advances in in vitro diagnostic assays during the last decade, ELISAs have be

116 The current functional diagnostic assays employ inhibition of activated C1s; ho

117 protocol developed here can be applied as a diagnostic assay, facilitating monitoring of Vgsc CN in

118 onal connectivity magnetic resonance imaging diagnostic assay for autism.

119 te and speed up an important and widely used diagnostic assay for bloodstream infections.

120 The standard diagnostic assay for bovine tuberculosis, the intraderma

121 A rapid diagnostic assay for CaPV would be useful for disease su

122 The CRAG LFA is an accurate diagnostic assay for CSF and should be considered for po

123 roviding the basis of an improved commercial diagnostic assay for EIAV infection of horses.

124 Use of sequencing-based genotyping as a diagnostic assay for human immunodeficiency virus (HIV)

125 We have developed a new diagnostic assay for limb girdle muscular dystrophy 2B a

126 demand for a simple broad-spectrum molecular diagnostic assay for pathogenic bacteria.

127 Specific IFN-gamma detection is a novel diagnostic assay for previous C. burnetii infection and

128 PSA structures could form a basis for a new diagnostic assay for prostate cancer.

129 This provides a quick and highly reliable diagnostic assay for PWS and AS, which is based on DNA-m

130 To develop a rapid molecular diagnostic assay for PWS, we tested the expression of th

131 Development of a valid diagnostic assay for quick detection (in less than an ho

132 Proof of concept for a novel diagnostic assay for rubella virus (RUB) based on RUB re

133 rred to here as OSOM) is a new point-of-care diagnostic assay for T. vaginalis that uses an immunochr

134 This is the first diagnostic assay for the detection of aMPV-C-specific an

135 e of an RNA aptamer for the development of a diagnostic assay for the detection of chemical residues

136 a fully automated sample-to-answer molecular diagnostic assay for the detection of influenza A, influ

137 iable, sensitive, and specific point-of-need diagnostic assay for the diagnosis of DENV in clinics an

138 usly reported, as well as a highly sensitive diagnostic assay for the ultratrace quantitation of a ph

139 tocol yields a rapid, sensitive, and precise diagnostic assay for the ultratrace quantitation of a th

140 In an effort to develop a rapid diagnostic assay for tularemia, we investigated the use

141 This work would open the door to real-time diagnostic assays for a wide range of diseases, but also

142 y been used to improve the design of several diagnostic assays for bacterial pathogens.

143 rovide alternative approaches to develop POC diagnostic assays for broad applications in medicine, th

144 and have implications for developing robust diagnostic assays for cancer patient stratification.

145 in enhancing the sensitivity of blood-based diagnostic assays for CWD and other TSEs.

146 r more sensitive, fast and/or less expensive diagnostic assays for dengue.

147 hich has allowed the development of standard diagnostic assays for detection of serum autoantibodies-

148 Rapid, reliable, and easy-to-use diagnostic assays for detection of Zaire ebolavirus (ZEB

149 velopment of simple and affordable molecular diagnostic assays for infectious diseases, especially in

150 enotyping approaches for rapid detection and diagnostic assays for molecular epidemiological and clin

151 Available diagnostic assays for Mycobacterium avium subsp. paratub

152 onsiderations when developing field-portable diagnostic assays for near-patient environments.

153 Currently, diagnostic assays for nucleic acids must be individually

154 Rapid diagnostic assays for PfCRT mutations are already employ

155 esigned an array of cpn60-targeted molecular diagnostic assays for SbGP/MPV phytoplasma.

156 ities and specificities of several different diagnostic assays for Streptococcus pneumoniae were asse

157 ew types necessitate regular updating of the diagnostic assays for the accurate and comprehensive det

158 es-specific rRNA sequences have been used in diagnostic assays for the detection and identification o

159 Rapid and sensitive diagnostic assays for the detection of tuberculous mycob

160 oglobin (HbA1c) is one of the most important diagnostic assays for the long-term mark of glycaemic co

161 Novel diagnostic assays for tuberculosis have conventionally b

162 ress has been made in the development of new diagnostic assays for tuberculosis in recent years.

163 a simple, low-cost, alternative to existing diagnostic assays for tuberculosis screening in HIV-infe

164 Current serological diagnostic assays for typhoid fever are based on detecti

165 viral (ARV) therapy guidelines and designing diagnostic assays for use in regions where standard geno

166 mplification strategy aimed toward threshold diagnostic assays for use in resource-limited settings i

167 and cancer, and for development of companion diagnostics assays for individualized medicine.

168 ulted in the need for sensitive and specific diagnostic assays, fully validated for the detection of

169 ry data indicate that, when PCR-based fungal diagnostic assays guide antifungal therapy, they may low

170 The lack of commercially available diagnostic assays has limited widespread routine testing

171 previous associated lack of rapid, sensitive diagnostic assays, has impaired recognition of AdV infec

172 Recently, diagnostic assays have been developed to detect platelet

173 Sensitive diagnostic assays have increased the detection of viruse

174 d probes for use in probe-based nucleic acid diagnostic assays (i.e., PCR-ELISA).

175 ormed with a commercially available in vitro diagnostic assay (ImmuKnow; Viracor-IBT Laboratories, Le

176 esent technologies in on-site or at home POC diagnostic assays implemented in paper-based microfluidi

177 Results of diagnostic assays implicated the household transmission

178 quantum dots may enable more simple, robust diagnostic assays in the future.

179 These vectors may also be useful in diagnostic assays in which infectious VEEV is undesirabl

180 viduals, HEV IgG was found in 4.5% by the MP Diagnostics assay, in 29.5% by the Axiom Diagnostics ass

181 s advance has enabled the development of new diagnostic assays, including in situ hybridization, PCR

182 infection was confirmed by a combination of diagnostic assays, including molecular tests, immunohist

183 rmeasures (vaccines, therapeutic agents, and diagnostic assays), infrastructure, and human resources.

184 e variation for the performance of molecular diagnostic assays is not well studied.

185 cs-based approach to the development of LAMP diagnostic assays is the first of its kind for fungi and

186 e have developed a multiplex allele-specific diagnostic assay (MASDA) for analysis of large numbers o

187 This diagnostic assay may also have veterinary applications d

188 Comprehensive diagnostic assays must therefore identify all possible D

189 econdition for the successful development of diagnostic assays of cerebrospinal fluid (CSF) biomarker

190 mise as vaccines and are being developed for diagnostic assays of other viruses.

191 Traditional diagnostic assays often lack sensitivity and can be diff

192 Both antibodies are used in Abbott diagnostic assays on AxSYM, IMx, and Architect platforms

193 ial IgA anti beta2GPI antibodies (abeta2GPI) diagnostic assays on specimens from individuals suspecte

194 nsufficient for successful implementation in diagnostic assays or as therapeutic agents.

195 This study therefore reports an advanced diagnostic assay performed on an integrated microfluidic

196 Rapid, accurate POC diagnostic assays play a crucial role in developing coun

197 Rapid, sensitive and specific diagnostic assays play an indispensable role in determin

198 To demonstrate the clinical utility of the diagnostic assay presented, a panel of lower RTI samples

199 The RT-PCR and antigen-capture diagnostic assays proved very effective for detecting eb

200 Medical diagnostic assays provide exquisite sensitivity and prec

201 me highly promising for future point-of-care diagnostic assays, pushing sensitivity towards single-mo

202 ification of nucleic acids binding proteins, diagnostic assays requiring release of the probe-target

203 portant new opportunities for development of diagnostic assays, sequential bioprocessing, and lab ass

204 by using any criteria and a highly sensitive diagnostic assay should be part of any chlamydial preven

205 ches to the delivery of sensitive yet rugged diagnostic assays specific for emerging viruses, to hast

206 Current diagnostic assays, such as the Abbott HAVAB test, used t

207 uss the clinical range, diagnostic criteria, diagnostic assay systems, and treatment options for this

208 econd-generation and new rapid point-of-care diagnostic assays take advantage of recent genetic and m

209 In this study, a novel real-time PCR diagnostic assay targeting the smpB gene was designed to

210 n effort to develop a new class of molecular diagnostic assay that can rapidly assess drug resistance

211 ibe a multiplex droplet digital PCR clinical diagnostic assay that concurrently distinguishes between

212 We have fabricated a point of care rapid diagnostic assay that employs fluorescent, micellar sili

213 We describe a diagnostic assay that simultaneously monitors for reject

214 The development of a rapid H. influenzae diagnostic assay that would allow for the implementation

215 l flow immunoassays (LFIs) are point-of-care diagnostic assays that are designed for single use outsi

216 Point-of-care diagnostic assays that are rapid, easy-to-use, and low-c

217 There is a need for culture-free diagnostic assays that can be carried out rapidly, and m

218 Diagnostic assays that can be used in conjunction with r

219 ults of this study will aid in the design of diagnostic assays that can detect prion disease across t

220 enerated in the study can be used to improve diagnostic assays that differentiate HSV-1 from HSV-2 in

221 is challenging, and the definitive serologic diagnostic assay, the microscopic agglutination test, is

222 id output for which there is already a known diagnostic assay, then that single assay could be easily

223 sodB target may offer an improved molecular diagnostic assay to detect Ehrlichia spp.

224 hese signatures can be used as the basis for diagnostic assays to detect and genotype microbes in bot

225 is-a-vis protective immunity, the ability of diagnostic assays to detect novel variants, and the poss

226 This finding provides a basis for developing diagnostic assays to differentiate species of borrelia t

227 Rapid diagnostic assays to distinguish more common infectious

228 al need for noninvasive, easy to administer, diagnostic assays to help assess whether a prostate biop

229 Noninvasive diagnostic assays to improve current late and nonspecifi

230 reagents in the preparation of vaccines and diagnostic assays to protect against and diagnose Lyme d

231 f heritable variation in resistance and that diagnostic assays to test the importance of other resist

232 he different M. bovis doses, suggesting that diagnostic assays (tuberculin skin test and IFN-gamma te

233 specimen quality and the sensitivity of the diagnostic assay used have a significant impact on deter

234 y dramatically impact the sensitivity of the diagnostic assay used.

235 sed devices can be an essential component of diagnostic assays used at the point-of-care.

236 rove the reliability of a group of important diagnostic assays used in the evaluation of systemic rhe

237 The portfolio of diagnostic assays used in the GEMS study can be broadly

238 Current diagnostic assays used to identify CA-MRSA strains are b

239 atments can be linked to the approval of new diagnostic assays used to measure efficacy or to predict

240 Here, we describe a multi-marker diagnostic assay using 5 markers (ARPC2, FN1, RGS1, SPP1

241 The development of diagnostic assays using highly targeted specific aptamer

242 t human pathogenic Fusarium in a single-well diagnostic assay, using flow cytometry and fluorescent m

243 Two rapid diagnostic assays, utilizing two different Luminex flow

244 Using this design, in a single diagnostic assay, we tested samples for 66 cystic fibros

245 sition, the amplification conditions for the diagnostic assay were not affected.

246 Diagnostic assays were performed in 4,169 at-risk person

247 gent need for a simple and rapid serological diagnostic assay which can differentiate between antibod

248 tor can be used to standardize aspergillosis diagnostic assays which detect and/or quantify nucleic a

249 the development and evaluation of molecular diagnostic assays, which continue to play an important r

250 Currently available diagnostic assays, which include polymerase chain reacti

251 n from a source rich in adult AChR in the MG diagnostic assay will increase the yield of positive res

252 Hence, a diagnostic assay with easy visualization of the amplifie

253 he approach described is applicable to other diagnostic assays with imperfect detection.

254 for the further development of point-of-care diagnostic assays with low-cost, robust reagents and sim

255 ics may lead to development of user-friendly diagnostic assays with simple readouts.

256 moniae should be confirmed using one or more diagnostic assays with well-documented high (e.g., > or

257 e internal control clone to be loaded into a diagnostic assay without negatively affecting it.

258 d employed directly for downstream molecular diagnostic assays without any further processing.

259 tbreak of any magnitude, a field-based rapid diagnostic assay would allow proper patient transport an